Clinical study of the administration method of antithrombin agent

Clinical study of the administration method of antithrombin agent - Clinical study of the administration method of antithrombin agent

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018280

Enrollment

100

Registered

2015-07-21

Start date

2015-07-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis indused disseminated intravascular coagulation

Interventions

AT agent is administered at 1500 U once per day for 3 days AT agent is administered by continuous infusion 1500 U per day for 3 days, after 1000 U loading dose is administered

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. sepsis 2. JAAM DIC score is 4 or greater 3. AT activity is less than 70

Exclusion criteria

Exclusion criteria: 1. other DIC agent for DIC treatment 2. use of anticoagulants, antiplatelet agents, antithrombotics, exception of heparin locks, heparin flushes or deep-vein thrombosis prophykaxis, and anticoaglants for renal replacement therapy

Design outcomes

Primary

Measure	Time frame
Disseminated intravascular coagulation resolution rates	—

Secondary

Measure	Time frame
28-day survival rate, AT activity change	—

Countries

Japan

Contacts

Public ContactHiroyuki Takahashi

Tokyo women's medical university medical center east, Emergency and Critical Care Center

htakahashi-tmd@umin.ac.jp03-3810-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026